Sign up
Pharma Capital

Boardroom reshuffle at Ergomed

Jan Petracek will fill the void left by Neil Clark, chief executive of Ergomed’s PrimeVigilance subsidiary, who is moving to Destiny Pharma
chairs around a meeting table
Clark will remain on the board of PrimeVigilance as a non-executive director and consultant

Drug research specialist Ergomed Plc (LON:ERGO) has told investors that the chief executive of its PrimeVigilance subsidiary, Neil Clark, is stepping down from his position.

After eight years with the company, Clark will vacate his post on Monday (16 April) to become chief executive at Destiny Pharma.

He will remain on the board of PrimeVigilance as a non-executive director and consultant.

Stay up to date with the latest Proactive news by signing up to our newsletter

Jan Petracek will replace Clark and step into the role of chief executive of the subsidiary straight away.

Petracek joined the company last November as chief executive of European PharmInvent Services following its acquisition and subsequent integration into PrimeVigilance.

“We are fortunate to have in the wings a replacement CEO of the calibre of Jan Petracek,” said Ergomed chief executive Miroslav Reljanovic.

“As founder of PharmInvent and former regulator at EMA, his unique combination of entrepreneurship and specialist pharmacovigilance expertise will serve to drive forward our pharmacoviglance businesses.”

View full ERGO profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.